Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Begins Clinical Trials for its First Genomically- Designed Drug

SAN FRANCISCO, Nov. 28 – Millennium Pharmaceuticals on Tuesday announced it had begun Phase I clinical trials for its first molecule directed against a genomically- derived target for metabolic disease.

The compound, called MLN4760, was synthesized by Millennium and was designed with the hope of providing a treatment for obesity. Millennium, based in Cambridge, Mass., partnered with Abbott Park, Ill.-based Abbott Laboratories in the development of the drug.

“With MLN4760 entering human trials, we realize an important company goal of bringing our first genomically-derived target into clinical development,” Robert Tepper, chief scientific officer, at Millennium, said in a statement. “In addition, MLN4760 represents a major milestone in the Abbott-Millennium partnership and highlights the strength of the alliance in using proprietary genomic and chemical technology platforms to discover and validate druggable targets and to move them through an expedited drug discovery process.”

The Phase I clinical trial is the first step in assessing the safety and efficacy of the drug in humans.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.